Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Innatera Nanosystems, a Netherlands-based developer of processing chips catered to sensors spun out of Delft University of Technology (TU Delft), has received €5m ($6m) of seed funding from investors led by venture fund MIG Verwaltungs and backed by Btov’s Industrial Technologies Fund. Innatera is working on computer processors to enable artificial intelligence to run from internet-connected sensors as opposed to from the cloud. The funding will help scale recruitment and its R&D programme with a view of servicing certain contracts throughout next year.
TXP Medical, the Japan-based developer of a patient information management system called Next Stage ER, has closed a ¥250m ($2.4m) series A round featuring University of Tokyo’s Edge Capital Partners vehicle.
Emergence Therapeutics, a Germany-based cancer antibody-drug conjugate (ADC) developer spun out through regional tech transfer office Satt Sud-Est, has closed a second seed round involving government-owned investment bank Bpifrance’s InnoBio 2.  The deal was led by public-private partnership High-Tech Gründerfonds and also included corporate-backed investment fund Gründerfonds Ruhr, biopharmaceutical firm Heidelberg Pharma, financial services firm NRW.Bank, investment firm Idinvest Partners and venture firm Kurma Partners. State support came through the German federal government’s €2bn ($2.4bn) startup funding programme. The seed capital will go to advancing Emergence’s lead candidate, Nectin-4, and additional ADC-based drugs. Emergence raised an inaugural seed round from the same investors as its latest round, excepting the German state, in November 2019 after securing capital from Kurma Partners at an undisclosed date.
Ball Wave, a Japan-based ball-shaped sensor producer exploiting Tohoku University innovations, has secured an undisclosed amount from automotive component manufacturer Toyoda Gosei. The pair will collaborate to employ Toyoda Gosei’s surface treatments to try to enhance Ball Wave’s ball sensors, which exploit surface acoustic waves to detect their surroundings. Toyoda Gosei also hopes to explore a potential virus detector using sensors and UV LED technology.
GeneVentiv Therapeutics, a US-based gene therapy developer, has been spun out of University of North Carolina-Chapel Hill to progress research into treating the blood clotting disorder haemophilia, according to the News and Observer. GeneVentiv aims to commercialise the scientific investigations of Chengwen Li, a research associate professor at UNC-Chapel Hill’s Department of Paediatrics. The spinout expects its candidate to begin clinical testing in mid-2022.